跳至主要内容
临床试验/IRCT20240501061618N1
IRCT20240501061618N1招募中2 期

Investigating the efficacy and safety of Curcumin on the prevention of non-alcoholic fatty liver disease (NAFLD) in patients with non-metastatic breast cancer receiving tamoxifen

Esfahan University of Medical Sciences0 个研究点目标入组 44 人开始时间: 待定最近更新:
适应症

试验速览

阶段
2 期
状态
招募中
入组人数
44

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
18 years 至 no limit(—)
性别
Female

入选标准

  • Women with non-metastatic breast cancer whose pathology is positive in terms of hormone receptors and are treated with tamoxifen.
  • Normal liver enzymes
  • Not having viral hepatitis
  • Not having a history of alcohol consumption
  • Not using drugs with hepatotoxicity such as methotrexate, amiodarone, valproic acid, anabolic steroids, as well as the use of anticoagulant and antiplatelet drugs.
  • Insensitivity to curcumin drug
  • No history of chemotherapy

排除标准

  • The patient's unwillingness to continue the study
  • Having liver diseases during the study
  • The use of drugs with hepatotoxicity such as methotrexate, amiodarone, valproic acid, anabolic steroids, as well as the use of anticoagulant and antiplatelet drugs after the start of the study.
  • Suffering from any related disease and distorting the results during the study
  • Allergic to curcumin drug
  • Development of Metastasis during the study

研究者

相似试验